Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 4/20 | 0.64 |
| ▸ | CHRNG | P07510 | 4/20 | 0.64 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.64 |
| ▸ | CHRND | Q07001 | 4/20 | 0.64 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647437 | 0.86 | GRIA1 (0.62) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL9447495 | 0.85 | CHRNA1 (0.54) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| Hydrochloric Acid SCHEMBL2551823 | 0.85 | GRIA1 (0.61) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL9447534 | 0.85 | TRPV1 (0.65) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL18086637 | 0.84 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL9785795 | 0.84 | TRPV1 (0.68) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL7323616 | 0.83 | CHRNA1 (0.67) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL9447522 | 0.83 | POLB (0.57) | CHRNA1CHRNGCHRNB1CHRNDCA12 | |
| SCHEMBL14198712 | 0.82 | TRPV1 (0.56) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL9447601 | 0.82 | TRPV1 (0.52) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-5218000-A | Nervous system disorders, antiischemic agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-06-08 | — | — | US | claimed |
| US-12121526-B2 | Targeting NCCA-ATP channel for organ protection following ischemic episode | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-20220193096-A1 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-23 | — | — | US | disclosed |
| US-20210113589-A1 | TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-04-22 | — | — | US | disclosed |
| US-10898496-B2 | Targeting NCCa-ATP channel for organ protection following ischemic episode | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-26 | — | — | US | disclosed |
| US-20190117672-A1 | TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-04-25 | — | — | US | disclosed |
| US-20190111137-A1 | METHODS FOR ANTAGONISTS OF A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-04-18 | — | — | US | disclosed |
| US-10166244-B2 | Targeting NCCA-ATP channel for organ protection following ischemic episode | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-01-01 | — | — | US | disclosed |
| WO-2005042475-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | SENTION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| EP-0361687-B1 | Therapeutic polyamine-amides | BRITISH TECH GROUP (GB) | 1993-10-27 | — | — | EP | disclosed |
| US-5218000-A | Nervous system disorders, antiischemic agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0361687-A1 | Therapeutic polyamine-amides | BTG INTERNATIONAL LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0360437-A1 | Biocidal polylamine-amides | BTG INTERNATIONAL LIMITED (GB) | 1990-03-28 | — | — | EP | disclosed |
| WO-1990001875-A1 | BIOCIDAL POLYAMINE-AMIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-03-08 | — | — | WO | disclosed |
| WO-1990002114-A1 | THERAPEUTIC POLYAMINE-AMIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | CHRNA1 338/4885CHRNG 1078/4885CHRNB1 478/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | CHRNA1 226/4885CHRNG 229/4885CHRNB1 216/4885 |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | ACHE, BCHE, CHAT | CHRNA1 71/4885CHRNG 22/4885CHRNB1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.